Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

SSSE:600267
12.85
CNY
+0.02
(+0.16%)
1.07EPS
11.09P/E
13.87BMarket Cap
Mar 26Next Earn

Total Valuation

CNY

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A carries a market capitalization of 13.87B, placing it among publicly traded companies globally. Its enterprise value stands at 14.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap13.87B
Enterprise Value14.50B

Important Dates

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for March 26, 2027.

Earnings Date3/26/2027

Share Statistics

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A has 1.18B shares outstanding.

Shares Outstanding1.18B

Valuation Ratios

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 11.09. The price-to-sales ratio is 1.49, and the price-to-book ratio stands at 1.46.

PE Ratio11.09
PS Ratio1.49
PB Ratio1.46
P/TBV Ratio1.59

Enterprise Valuation

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 8.91 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.91 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.50B versus a market cap of 13.87B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.59
EV / EBITDA8.91
EV / EBIT8.91

Financial Position

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 15.82, indicating elevated leverage, while an interest coverage ratio of 25.55 demonstrates strong ability to service its debt obligations.

Current Ratio1.09
Quick Ratio0.31
Debt / Equity15.82
Debt / EBITDA0.95
Interest Coverage25.55

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 13.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.44 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.61, useful for judging operating efficiency across full business cycles. The company generates approximately 1.05M in revenue per employee across its workforce of 8,751.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.72 indicates how many times Zhejiang Hisun Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)13.72
Return on Assets (ROA)8.34
Return on Invested Capital (ROIC)10.44
Return on Capital Employed (ROCE)10.61
Revenue Per Employee1.05M
Employee Count8,751.00
Inventory Turnover2.72

Taxes

CNY

Over the twelve months ended September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A recorded 359.72M in income tax expense. That works out to an effective tax rate of 22.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.59B, leaving 1.23B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax359.72M
Effective Tax Rate22.56

Stock Price Statistics

CNY

As of the close on November 17, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A's stock has gained approximately 15.25% over the past 52 weeks. The 50-day moving average sits at 12.31, while the 200-day moving average is 11.33.

52-Week Price Change15.25%
50-Day Moving Average12.31
200-Day Moving Average11.33

Income Statement

CNY

Over the twelve months ended September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A generated 9.15B in revenue and converted that into 1.23B in net income, yielding earnings per share of 1.07. EBITDA reached 1.63B, while operating income came in at 1.66B.

Revenue9.15B
Gross Profit4.97B
Operating Income1.66B
Pretax Income1.59B
Net Income1.23B
EBITDA1.63B
EBIT1.63B
Earnings Per Share (EPS)1.07

Balance Sheet

CNY

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A holds 1.18B in cash and equivalents against 1.55B in total debt, resulting in a net debt position of -40.08M. Total book value stands at 9.51B, with working capital of 328.89M providing operational flexibility.

Cash & Cash Equivalents1.18B
Total Debt1.55B
Net Debt-40.08M
Equity (Book Value)9.51B
Book Value Per Share8.06
Working Capital328.89M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-503.35M

Margins

Over the twelve months ended September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A posted a gross margin of 54.38, reflecting its pricing power and cost economics. The operating margin of 18.11 and net profit margin of 13.40 provide insight into operational efficiency.

Gross Margin54.38
Operating Margin18.11
Pretax Margin17.43
Profit Margin13.40
EBITDA Margin17.79

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A paid dividends of 0.26 per share. The dividend payout ratio of 24.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 10.02, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Hisun Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share0.26
Payout Ratio24.10
Shareholder Yield10.02

Stock Splits

Zhejiang Hisun Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 25, 2012 with a 5:8 split ratio.

Last Split Date5/25/2012
Split Ratio5:8

Scores

As of September 30, 2026, Zhejiang Hisun Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.61